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Abstract Sclerostin, bone formation antagonist is in the
spotlight as a potential biomarker for diseases presenting
with associated bone disorders such as chronic kidney dis-
ease (CDK-MBD). Accurate measurement of sclerostin is
therefore important. Several immunoassays are available to
measure sclerostin in serum and plasma. We compared the
performance of three commercial ELISA kits. We measured
sclerostin concentrations in serum and EDTA plasma
obtained from healthy young (18–26 years) human subjects
using kits from Biomedica, TECOmedical and from R&D
Systems. The circulating sclerostin concentrations were
systematically higher when measured with the Biomedica
assay (serum: 35.5 ± 1.1 pmol/L; EDTA: 39.4 ± 2.0
pmol/L; mean ± SD) as compared with TECOmedical
(serum: 21.8 ± 0.7 pmol/L; EDTA: 27.2 ± 1.3 pmol/L)
and R&D Systems (serum: 7.6 ± 0.3 pmol/L; EDTA:
30.9 ± 1.5 pmol/L). We found a good correlation between
the assay for EDTA plasma (r[ 0.6; p\ 0.001) while in
serum, only measurements obtained using TECOmedical
and R&D Systems assays correlated significantly (r = 0.78;
p\ 0.001). There was no correlation between matrices
results when using the Biomedica kit (r = 0.20). The vari-
ability in values generated from Biomedica, R&D Systems
and TECOmedical assays raises questions regarding the
accuracy and specificity of the assays. Direct comparison of
studies using different kits is not possible and great care
should be given to measurement of sclerostin, with trace-
ability of reagents. Standardization with appropriate mate-
rial is required before different sclerostin assays can be
introduced in clinical practice.
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Introduction
Sclerostin is a 190-residue secreted protein member of the
DAN/Cerberus protein family. Sclerostin was discovered
as a product of the SOST gene causing sclerosteosis [1, 2],
and van Buchem syndrome [3, 4], and later confirmed in
mice in which the SOST gene had been deleted [5] or
overexpressed [6]. Sclerostin is secreted by osteocytes [7]
and articular chondrocytes [8] and its absence favours bone
formation by lack of inhibition of the canonical Wnt/b-
catenin signalling [9–11], leading to osteoblast differenti-
ation, proliferation and activity [5, 12].
Circulating sclerostin concentrations are altered in
metabolic bone diseases. Sclerostin concentrations are
increased in disorders such as hypoparathyroidism [13],
type II diabetes [14, 15] cancer induced bone disease [16]
and Paget’s disease [17] and decreased in primary hyper-
parathyroidism [18–20] and ankylosing spondylitis [21],
although recently increased disease activity in ankylosing
spondylitis has been associated with higher sclerostin
concentrations [22]. Sclerostin may also play a role of
importance in patients with chronic kidney disease asso-
ciated with mineral and bone disorder (for review see [23]).
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High concentrations of circulating sclerostin are suggested
to be associated with arterial stiffness, cardiovascular cal-
cification and inflammation, leading to higher morbidity
and mortality. However, the results so far are controversial.
Measurement of circulating sclerostin may be helpful in
the diagnosis of bone remodelling disorders and assessment
of therapeutic effectiveness but concordant results between
various assays are necessary for clinical trial comparison.
Several assays are available for measurement of sclerostin
using human blood. We tested and compared three plate-
based enzyme-linked immunosorbent assays (ELISA) in
serum and ethylene diamine tetra acetic acid (EDTA)
plasma samples from healthy young individuals.
Materials and Methods
Reagents
ELISA kits were purchased from Biomedica, Vienna,
Austria (Sclerostin #BI-20492 lot Y143), R&D Systems,
Abingdon, United Kingdom (Quantikine Human SOST
immunoassay #DSST00, lot 318592) and TECOmedical,
Sissach, Switzerland (Human Sclerostin EIA, High Sensi-
tivity #TE1023HS, lot 012455).
Samples
Anonymised samples from healthy volunteers (aged
18–26 years) were provided by the Ministry of Defence
collected in accordance with the Ministry of Defence
Research Ethics Committee (MODREC-165). Forty-six
serum samples and 27 matching EDTA plasma samples
were analysed and sclerostin concentrations were measured
following each manufacturer’s instructions.
Methods and Statistical Analysis
For the Biomedica sclerostin ELISA, 150 lL assay buffer,
20 lL standards, controls and samples and 50 lL antis-
clerostin antibody were loaded per well. Plates were
incubated for 24 h at room temperature (RT = 22 C) in
the dark. The following day, wells were washed five times
with 300 lL of the wash buffer provided and 200 lL
conjugate was added and incubated in the dark for 1 h.
Wells were washed five times with 300 lL of wash buffer,
200 lL 3,30,5,50-tetramethylbenzidine (TMB) was added
per well, and colour was allowed to develop for 30 min.
Stop solution (50 lL) was added and absorbance read at
450 nm with reference at 630 nm.
With the TECOmedical high sensitivity kit, plates were
washed for 2 min at RT with 400 lL wash buffer (pro-
vided) and blot dried. Wells were then loaded with 25 lL
standards, controls and samples, followed by 50 lL matrix
and 50 lL antibody solutions. Plates were sealed and
incubated on a shaker at 500 rpm for 4 h. Wells were
washed four times with 400 lL wash buffer and then
developed in the dark with 100 lL TMB solution at RT for
30 min. The reaction was stopped with 100 lL of stop
solution. Absorbance was measured at 450 nm with refer-
ence at 630 nm.
For the R&D Systems Sclerostin Quantikine ELISA,
100 lL of assay diluent was added to each well, followed
by 50 lL of standards, controls and samples. Plates were
sealed and incubated for 2 h at RT on a shaker at 500 rpm.
Plates were then washed four times with 400 lL of wash
buffer, 200 lL of TMB solution added to the wells and
colour was allowed to develop for 30 min in the dark at
RT. Finally, 50 lL of stop solution was added to each well
and absorbance read at 450 nm with reference at 560 nm.
Results are expressed in pmol/L using a multiplying
conversion factor of 44 from ng/mL to pmol/L. Values are
given as mean ± SD. Data were analysed using SPSS for
windows version 22.0.0.2. Agreement between assays and
between the serum and EDTA values were assessed using
Passing-Bablock regression, Bland–Altman plots and con-
cordance correlation (CCC) analysis.
Results
Quality Assessment
All assays were performed in accordance with the manu-
facturer’s instructions and complied with our standard
operating procedures for good laboratory practice. Inter-
assay performance was assessed by calculating the mean,
SD and CV % of QC material on 6 plates from the same lot
over 2 days for Biomedica and TECOmedical and 3 plates
over 2 days for R&D Systems. CVs were\6 % except for
R&D Systems at 15.3 pmol/L where a CV of 14 % was
observed (Table 1). We also crossed over the QC material
and observed that both R&D Systems and TECOmedical
were close to expected target for each other’s QC (except
for low level QC TECOmedical), however, they both
underestimated Biomedica QC by 25–43 %. QCs from
TECOmedical and R&D Systems were mainly overesti-
mated when measured with the Biomedica kit. In order to
estimate the intra-assay imprecision, we calculated the
average CV from duplicates of samples and also run a
serum pool four times on two different plates. Results,
presented in Table 1, showed that TECOmedical per-
formed best with CV\ 4.5 % and only 1 sample with a
CV[ 10 %. However, both Biomedica and R&D Systems
showed high CVs on serum and EDTA with CVs up to
35 % for R&D Systems and 69 % for Biomedica). Similar
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results were obtained with the serum pool run in quadru-
plicate as Biomedica showed a CV of 33 %.
We assessed the linearity (Table 2) of the assays by
diluting serum and EDTA samples by two-, four- and
eight-fold using the sample diluent provided in the kits.
Upon 1:2 and 1:4 dilutions, sclerostin concentrations were
111 & 89 % and 97 & 103 % of the expected concentration
for R&D Systems and TECOmedical, respectively. Upon
1:8 dilution TECOmedical sclerostin concentration was
107 % of the expected concentration for TECOmedical;
however, as the neat concentration of the samples were
already very low, 1:8 dilution lead to irrelevant values
when measured using the R&D Systems assay. When using
the Biomedica assay, samples were consistently over-re-
covered upon dilution (146, 147 and 139 % after 1:2; 1:4
and 1:8 dilution).
Spiked recovery (%) was determined by adding a known
quantity of purified sclerostin (from QC material with each
assay) to samples containing a range of endogenous
sclerostin. Results (Table 2) were very similar between the
kits and close to 100 % with Biomedica: 100.6 ± 4.1 %;
TECOmedical: 97.4 ± 4.7 % and R&D Systems:
97.6 ± 3.0 %.
Sclerostin Measurements
Samples were analysed at the same time using all three kits
so differences could not be attributed to differences in
sample handling such as freeze/thaw cycles. For each
provider, assays were performed using the same lot number
and the samples had only been through one freeze–thaw
cycle. Recommended maximum freeze–thaw cycles were 4
for Biomedica and 3 for TECOmedical (no data available
for R&D Systems). Table 3 shows mean ± SEM of scle-
rostin as well as minimum and maximum values obtained
with the different assays and depending on collection tube.
We obtained significantly different values for sclerostin
concentrations measured in EDTA plasma samples by each
Table 1 Intra- and inter-assay
data for the measurement of
sclerostin using Biomedica,
TECOmedical and R&D
Systems kits
Intra-assay Mean of %CV ± SEM (maximum %CV) Serum pool
Serum (n = 46) EDTA (n = 27) % CV plate 1 and 2
Biomedica 8.2 ± 1.6* (68.8 %) 7.6 ± 1.2* (20.3 %) 33 and 9.9 %
TECOmedical 2.7 ± 0.4 (11.3 %) 2.7 ± 0.5 (8.9 %) 4.5 and 2.8 %
R&D Systems 5.0 ± 1.1 (35 %) 7.3 ± 1.0* (16.7 %) 9.2 and 3.9 %
Inter-assay Biomedica TECOmedical R&D Systems
Mean (pmol/L) 87.7 8.2 92.1 9.2 15.3 37.7
SD 2.8 0.4 3.6 0.2 2.2 2.2
CV 3.2 4.4 3.9 2.4 14.3 5.8
QC cross-over in pmol/L (deviation to target %)
Biomedica QC 23.6 (?187) 144.6 (?57) 18.3 (?98) 23.9 (?56) 44.3 (?17)
TECOmedical QC 50.2 (-43) 9.2 (-0.3) 14.5 (-5.3) 34.3 (-9.1)
R&D systems QC 65.6 (-25) 6.2 (-25) 88.3 (-4)
Intra-assay was estimated using the mean ± SEM of the CVs from samples run in duplicates and a serum
pool run six times on two different plates. Inter-assay was estimated by repeated measure of QC material on
different plates
Statistical significance, * p\ 0.05 as compared to TECOmedical
Table 2 Linearity and recovery
data for the measurement of
serum sclerostin using
Biomedica, TECOmedical and
R&D Systems kits
Linearity (% ± SEM) Recovery (% ± SEM)
1:2 1:4 1:8
Biomedica 146.7 ± 18.3* 147.4 ± 16.9* 139.1 ± 7.0* 100.6 ± 4.1
TECOmedical 97.2 ± 3.5 103.2 ± 3.8 107.1 ± 7.1 97.4 ± 4.7
R&D Systems 110.6 ± 18.6 88.5 ± 14.2 685.4 ± 79.1*** 97.6 ± 3.0
Linearity was assessed by diluting samples up to eight-fold. Recovery was assessed by spiking samples
with known concentration of QC material
Statistical significance, * p\ 0.05 Biomedica versus TECOmedical and R&D Systems, *** p\ 0.001
R&D Systems versus TECOmedical and Biomedica
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kit. The Biomedica assay detected the significantly highest
results up to a concentration of 32 pmol/L and on average,
29.5 % (p\ 0.001) and 19.8 % (p\ 0.001) higher than
TECOmedical and R&D Systems assays, respectively.
EDTA sclerostin measured by TECOmedical and R&D
Systems were not significantly different. Passing-Bablock
regression and concordance correlation analyses (Fig. 1
right panel; Table 4) showed a linear relationship with
systematic and proportional differences between the assays
when using the EDTA samples. Although R&D Systems
gave values 13.8 % lower than TECOmedical, we observed
a good correlation between the two assays when using
EDTA samples with Pearson coefficient of 0.96 but a poor
agreement between the two methods with CCC of 0.85
(95 % CI 0.738–0.912) and a bias correction of 0.88.
Bland–Altman plot showed that the bias was small and
similar across the range of concentrations. Biomedica
results did not correlate with the other kits and concordance
correlations were very poor (CCC of 0.46 and 0.33 versus
R&D Systems and TECOmedical, respectively, with 95 %
CI 0.223–0.627 and 0.153–0.486 and Pearson coefficient of
0.68 and 0.71; correction bias were 0.67 and 0.47). Bland–
Altman plots (Fig. 2) also showed the bias increased with
higher the concentration of sclerostin.
Larger discrepancies were observed with serum sam-
ples. Biomedica gave an average of 37.1 and 77.9 % higher
concentrations versus TECOmedical and R&D systems,
respectively (Fig. 1 left panel; Table 3); discrepancies
being up to 50 pmol/L (p\ 0.001). Biomedica results
showed very poor correlation with the two other kits with
extremely poor concordance between the results
(CCC\ 0.08 and Pearson correlation coefficient\ 0.29).
TECOmedical and R&D Systems correlated with r = 0.78,
however, R&D systems gave lower results (65 % on
average) and extremely poor value agreement (CCC of
0.08 95 %CI 0.041–0.113) and Cusum test for linearity
indicates significant deviation from linearity (p\ 0.05).
Bland–Altman plots (Fig. 3) showed a negative bias that
increased proportionally as the concentrations increases for
both R&D Systems versus TECOmedical and R&D Sys-
tems and Biomedica. When comparing TECOmedical to
Biomedica, Bland–Altman plot showed that the bias was
mainly present for high concentrations of sclerostin.
Matrix Effect
Serum sclerostin concentrations (Table 3) were signifi-
cantly lower than EDTA for TECOmedical (serum:
21.8 ± 4.8 pmol/L versus EDTA 27.2 ± 6.9 pmol/L
p\ 0.03) and for R&D Systems (serum: 7.6 ± 2.4 pmol/L
versus EDTA 19.0 ± 4.7 pmol/L p\ 0.01) which also
displayed a very low CCC of 0.04 although the correlation
coefficient was 0.85 in the Passing-Bablock analysis
(Table 4; Fig. 4). Passing-Bablock analysis also showed
good correlation but poor correspondence of serum and
EDTA results for TECOmedical (CCC of 0.78 95 %CI
0.63–0.87 and Pearson correlation coefficient of 0.9).
When using the Biomedica kit, serum and EDTA showed
poor correlation (0.20) with differences between -26.6 and
113.9 % and a no agreement with a very low CCC of 0.2.
Bland–Altman plots showed that there was virtually no
bias between EDTA and Serum measurements when using
the TECOmedical kit, there was a negative bias that pro-
portionally increased with increasing concentrations of
sclerostin when using R&D Systems kits and the bias was
present mainly at the highest concentrations for Biomedica,
however, the CI was larger than the two other kits.
Discussion
We analysed serum and matching EDTA plasma samples
from healthy young men and women aged 18–26 years
using commercially available kits from Biomedica,
TECOmedical and R&D Systems. In general the kits per-
formed according to the manufacturer’s inserts for inter-
assay characteristics (performed on QC material) as well as
spiked recovery. The Biomedica assay showed a poor lin-
earity on dilution of samples with diluted recovery of
145 %. It has been suggested that heparin as an anticoag-
ulant could interfere with the binding of sclerostin to pro-
teins such as LRP5/6 and the antibodies used in some
assays [24]; we therefore used only EDTA plasma and
serum samples in this evaluation. Overall, we found that
measurements on EDTA samples were more comparable
between assays (lower differences in values and better
correlations between kits) than on serum samples. This
Table 3 Sclerostin
concentrations measured with
R&D Systems, TECOmedical
and Biomedica kits in pmol/L
and presented as mean ± SEM
along with the minimum and
maximum values (and the SD)
Serum (SOST) pmol/L n = 46 EDTA (SOST) pmol/L n = 27
Mean ± SEM Min–max (SD) Mean ± SEM Min–max (SD)
Biomedica 35.5 ± 1.1**, 22.3–58.9 (7.3) 39.4 ± 2.0 22.9–71.1 (10.3)
TECOmedical 21.8 ± 0.7 11.4–32.6 (4.8) 27.2 ± 1.3 13.8–49.1 (6.9)
R&D Systems 7.6 ± 0.4** 2.7–13.2 (2.4) 30.9 ± 1.5 15.4–53.0 (7.8)
** p\ 0.001 versus TECOmedical;  p\ 0.001 versus R&D Systems
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difference could be due to the separation technique. During
coagulation in serum samples, clot formation removes
proteins such as fibrinogen from the blood sample poten-
tially trapping part of the sclerostin. During the clotting
process, platelets get activated inducing the release of
various metabolites, which can alter analyte levels relative
to plasma [25–27].
The Biomedica assay gave systematically the highest
results on samples or QC material from the two other kits.
R&D Systems, on the other hand, produced very low val-
ues when using serum samples. Cross-over measurement of
QC material showed that both R&D Systems and
TECOmedical were relatively accurate and close to the
expected target for each other’s QC, however, both
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Fig. 1 Passing-Bablock regression analysis for serum (left panel) and
EDTA (right panel) samples comparing the three different ELISA kits
for circulating sclerostin measurements. Dash line represents the
fitted regression line; dark grey dotted lines represent upper and lower
95 % confidence and light grey dotted line represent the identity line
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Table 4 Passing-Bablock and Lin’s concordance correlation analyses comparing sclerostin ELISA kits on EDTA and serum samples
EDTA Passing-Bablock regression analysis Concordance correlation analysis
Intercept 95 % CI Slope 95 % CI Cusum test CCC 95 % CI r Cb
R&D Systems versus TECOmedical -1.0 -4.68–1.73 0.9 0.81–1.0 No 0.846 0.738–0.912 0.964 0.878
Biomedica versus R&D Systems -5.7 -25.5–7.3 1.4 1.0–2.1 No 0.455 0.223–0.627 0.681 0.667
Biomedica versus TECOmedical -2.8 -22.0–6.0 1.5 1.2–2.7 No 0.330 0.153–0.486 0.710 0.464
SERUM Passing-Bablock regression analysis Concordance correlation analysis
Intercept 95 % CI Slope 95 % CI Cusum test CCC 95 % CI r Cb
R&D Systems versus TECOmedical 4.3 -0.3 to 8.4 2.6 1.7–2.8 Yes 0.077 0.041 to 0.113 0.780 0.099
Biomedica versus R&D Systems -2.3 -65.4 to 11.7 5.3 3.2–14.2 No 0.007 -0.006 to 0.02 0.175 0.041
Biomedica versus TECOmedical -1.9 -35.0 to 9.7 1.7 1.1–3.3 No 0.076 -0.008 to 0.158 0.288 0.263
CI confidence interval; CCC concordance correlation coefficient; r: Pearson correlation coefficient; Cb bias correction. EDTA results showed
good correlation between the kits (r[ 0.68). However, results obtained with the Biomedica kit using serum samples did not correlate with either
TECOmedical (r = 0.29) or R&D Systems (r = 0.18) and showed poor concordance (CCC\ 0.08)
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Fig. 2 Bland–Altman plots for
sclerostin concentrations in
EDTA plasma comparing the
three different ELISA kits.
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(and wide CI) compared to
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at the highest concentrations of
sclerostin
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underestimated Biomedica QC. The discrepancies, we
observed between the sclerostin concentrations (as for the
reference ranges) suggest that the three assays are mea-
suring different forms of the protein and/or the specificity
of the antibody used is different. As previously reported,
Biomedica and TECOmedical assays can be affected by
interfering substances [28] which may partly account for
the poor linearity and the high CVs observed when using
the Biomedica kit.
We found poor correlation (0.3) and no agreement of
values between TECOmedical and Biomedica assays using
serum samples. These results are conflicting with a similar
study from Costa et al. [28] who showed a correlation of
0.9 with systematic and proportional differences between
the two methods. This difference could be attributed to the
fact that Costa et al. used the Sclerostin TECO kit which
is the previous sclerostin assay developed by TECOmedi-
cal while we used the new version of the assay marked as
Human Sclerostin EIA High Sensitivity. This is a different
kit, with different antibodies and a different manufacturer’s
protocol, which could very well account for the differences
in the raw sclerostin values obtained. Also we used samples
from pre-menopausal (18–26 year-old) healthy participants
while previous studies used samples from a mix of younger
and older patients and/or suffering from bone-affecting
disorders. Concentrations of sclerostin measured using the
Biomedica ELISA, however, were very similar being
[30 pmol/L on average in both EDTA plasma and serum;
differences quoted are potentially attributable to variation
between kit lot numbers. The concentrations of sclerostin
we measured using the TECOmedical assay are *30 %
lower than previously published data in serum and EDTA
[24, 28] (but [30] in serum).
This is the first study comparing different kits that
included the ELISA assay from R&D Systems. The results
indicate comparable raw results and good correlation with
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TECOmedical when using EDTA plasma samples. Serum
values are lower with the results reflecting those obtained
with the Meso Scale Discovery platform [30] of
0.8–3 pmol/L, suggesting that the R&D System kit could
be detecting only intact sclerostin. More research is
required to answer this question, but variation between lot
numbers may be the cause of some of the differences
observed.
Given the differences between assays, the results and
reference ranges will be assay-specific and specific to
sample type. However, comparing mean sclerostin con-
centrations obtained with mean values quoted by manu-
facturers for healthy donors, values for TECOmedical were
within the expected reference range. Only 2 and 4 % of
samples, respectively, for serum and EDTA were above the
reference range for R&D Systems. However, 20 % of
serum samples were above the quoted reference range
when using the Biomedica assay. No reference range was
given for EDTA plasma samples by this manufacturer,
however, in their matrix comparison 8 EDTA samples were
analysed giving a mean at 18.2 pmol/L leading us to
believe a similar gap would be expected between our val-
ues and the reference range. This result is in accordance
with Moyse´s et al. [29] who found an extra 25 % of
hemodialysed patients were above the reference range
when using Biomedica versus TECOmedical. These dif-
ferences could have important consequences for patients
that are falsely classified as over the range or inversely as
presenting normal levels of sclerostin as we cannot to date
determine what each assay is actually measuring.
Following its discovery in 2001, interest in sclerostin
has expanded in recent years with over 100 publications in
2014. As the knowledge about structure and function of
sclerostin is progressively unveiled, sclerostin is being
suggested as a ‘‘predictor’’ and ‘‘biomarker’’ for diseases
such as chronic kidney disease (CKD) [31], aortic valve
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Fig. 4 Bland–Altman plots
comparing sclerostin
concentration in serum versus
EDTA plasma using the three
different ELISA kits.
TECOmedical showed very
little bias between serum and
EDTA samples. There was a
systematic and proportional
negative bias with the R&D
Systems assay (from -11 to
-38 pmol/L). The bias was
present mainly for the high
concentrations of sclerostin
using the Biomedica assays
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calcification [32], osteoporotic fracture [33] or spinal cord
injury induced osteoporosis [34]. In CDK in particular,
evidence points to a central role of sclerostin in the kidney–
bone–vascular axis. As the disease progresses, patients
with chronic kidney disease also suffer from vascular cal-
cification and osteodystrophy (CDK-MBD) leading to
higher morbidity and mortality. Although the exact path-
way is yet to be elucidated and results can be inconsistent,
two hypotheses have emerged. Bone-originating sclerostin
may have an indirect counter-regulatory action on the
vascular calcification via the regulation of the production
of other hormones and/or sclerostin may be produced
locally when the environment becomes calcifying (for
reviews see [23, 35, 36]). Circulating sclerostin concen-
trations have been reported to vary by sex, age, season and
severity of diseases and treatment. The variability in
measurement adds to the complexity in drawing conclu-
sions on the role of sclerostin.
As focus grows on sclerostin, authors are rightly being
cautious, as we are in this publication, highlighting the
need for a consensus and standardization, of the assays to
measure sclerostin before sclerostin assays can be used as
routine diagnostic tools for metabolic bone diseases. It may
be necessary to consider the use of external reference
materials for quality control and quality assurance of these
assays.
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